{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.6","upperLimit":"19.7","value":"12.0"}]}],"title":"Complete response rate (CR rate)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"13.2","upperLimit":"29.2","value":"20.4"}]}],"title":"Partial response rate (PR rate)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"108"}],"units":"Participants"}],"description":"Complete response and/or partial response by Positron Emission Tomography-Computed Tomography (PET-CT) assessed by an Independent Review Committee (IRC) utilizing the modified Lugano Classification Revised Staging System for malignant lymphoma (Cheson, 2014).","dispersionType":"95% Confidence Interval","groups":[{"description":"Subjects with Relapsed or Refractory CD30 positive Peripheral T-cell Lymphoma (PTCL).","id":"OG000","title":"Cohort A"}],"paramType":"NUMBER","populationDescription":"The full analysis set (FAS) followed the intent to treat (ITT) principle and consisted of all subjects who received at least one dose of AFM13.","reportingStatus":"POSTED","timeFrame":"Tumor assessment performed every 8 weeks for first 3 assessments, then every 12 weeks until documented disease progression (up to 46 months).","title":"Complete Response Rate and Partial Response Rate Assessed by Independent Review Committee Based on PET-CT","type":"SECONDARY","unitOfMeasure":"percentage"}